Issue link: https://www.e-digitaleditions.com/i/341135
Tablets & Capsules July 2014 17 Issue focus excipients Direct-to-press chewing gum Health in Gum directly compressible excipient combination for making chewing gum tablets delivers moisture-sensitive APIs and dietary supplements to people who have difficulty swallowing tablets or capsules, thus improving compliance. API release is faster than that of traditional gums due to lighter bonding of API to gum base. Powder can be mixed with API at room temperatures, making it suitable for heat-sensitive formulations. Tablets are made on standard equipment, and dedicated chewing-gum production equipment is not necessary. Product is manufactured under GMP conditions. Cafosa Gum, Barcelona, Spain. Tel. +34 934 100 300 Fax +34 933 214 405 www.healthingum.com Ion-exchange resins Ion-exchange resins for orally disintegrating tablets and other dosage forms offer advantages over taste-masking strategies that depend on sweeteners or flavor addi- tives, which may be undesirable for patients with diabetes, fructose intolerance, or aspartame intolerance (i.e., phenylketonurics). Poorly adsorbed flavor additives and non-digestible sweeteners can also produce laxative effect. Limiting dissolution of API in patient's mouth is an alternative that can be achieved via API-complexation using ion-exchange resins. Method binds API so release in salivary pH is insufficient to produce bitter taste, thus improving compliance. Dow Water and Process Solutions, Edina, MN. Tel. 952 914 1069 Fax 952 835 4969 www.dowwaterandprocess.com Adjustable-release matrix RetardCel powder matrix-agent includes sodium carboxymethyl cellu- lose and forms gel that slows diffusion and release of API. Diffusion rate is mediated by cellulose ethers. API release rate depends on viscosity of mixtures, with high-viscosity com- pounds forming harder gel and low-vis- cosity compounds forming softer gel. Powder can be used in direct-compres- sion (DC) and wet-granulated formula- tions. In DC applications, API, excipi- ents, and matrix agent are mixed in one step; in wet granulations, API is granu- lated first (to particles smaller than 400 microns) and then mixed with agent. Use level in tablets is 10 to 30 percent. Biogrund, Sterling, VA. Tel. 312 286 0578 www.biogrund.com d-FOCUS_16-21_Masters 7/2/14 11:07 AM Page 17